FGFR3 and hereditary endocrine growth disease: In DGD patients, growth disorders, especially defective matrix functions such as genetic alterations in genes (e.g., COL 1 A, COLA2), or alterations in receptor formation (FGFR3) contribute to bone fragility and low density which can precipitate pathological fracture [26, 42].